3/24
10:17 am
mbrx
Moleculin Biotech (MBRX) had its "buy" rating reaffirmed by HC Wainwright. They now have a $22.00 price target on the stock.
Medium
Report
Moleculin Biotech (MBRX) had its "buy" rating reaffirmed by HC Wainwright. They now have a $22.00 price target on the stock.
3/23
09:14 am
mbrx
Moleculin Hits 45 Subject Enrollment Milestone, Triggering Final Countdown to Mid-2026 MIRACLE Trial Data Readout [Yahoo! Finance]
Low
Report
Moleculin Hits 45 Subject Enrollment Milestone, Triggering Final Countdown to Mid-2026 MIRACLE Trial Data Readout [Yahoo! Finance]
3/23
08:31 am
mbrx
Moleculin Hits 45 Subject Enrollment Milestone, Triggering Final Countdown to Mid-2026 MIRACLE Trial Data Readout
Medium
Report
Moleculin Hits 45 Subject Enrollment Milestone, Triggering Final Countdown to Mid-2026 MIRACLE Trial Data Readout
3/19
08:10 pm
mbrx
Moleculin Reports Full Year 2025 Financial Results and Confirms Highly Anticipated 45-Patient Interim Data Unblinding in Pivotal MIRACLE Trial On Track for Mid-2026 [Yahoo! Finance]
Neutral
Report
Moleculin Reports Full Year 2025 Financial Results and Confirms Highly Anticipated 45-Patient Interim Data Unblinding in Pivotal MIRACLE Trial On Track for Mid-2026 [Yahoo! Finance]
3/19
08:36 am
mbrx
Moleculin Reports Full Year 2025 Financial Results and Confirms Highly Anticipated 45-Patient Interim Data Unblinding in Pivotal MIRACLE Trial On Track for Mid-2026
Low
Report
Moleculin Reports Full Year 2025 Financial Results and Confirms Highly Anticipated 45-Patient Interim Data Unblinding in Pivotal MIRACLE Trial On Track for Mid-2026
3/17
09:14 am
mbrx
Moleculin to Present at 38th Annual ROTH Conference [Yahoo! Finance]
Medium
Report
Moleculin to Present at 38th Annual ROTH Conference [Yahoo! Finance]
3/17
09:05 am
mbrx
Moleculin to Present at 38th Annual ROTH Conference
Medium
Report
Moleculin to Present at 38th Annual ROTH Conference
3/11
09:14 am
mbrx
Moleculin Releases Next CEO Corner Segment Highlighting MIRACLE Study [Yahoo! Finance]
Low
Report
Moleculin Releases Next CEO Corner Segment Highlighting MIRACLE Study [Yahoo! Finance]
3/11
09:00 am
mbrx
Moleculin Releases Next CEO Corner Segment Highlighting MIRACLE Study
Medium
Report
Moleculin Releases Next CEO Corner Segment Highlighting MIRACLE Study
2/19
08:39 am
mbrx
Moleculin Announces Exercise of Warrants for $8.3 Million Gross Proceeds
High
Report
Moleculin Announces Exercise of Warrants for $8.3 Million Gross Proceeds
2/18
08:20 am
mbrx
Moleculin MIRACLE Trial Delivers 40% Preliminary Blinded CRc Rate (n=30)
Medium
Report
Moleculin MIRACLE Trial Delivers 40% Preliminary Blinded CRc Rate (n=30)
2/17
08:35 am
mbrx
Moleculin Announces Notice of Allowance for Japanese Patent Covering Annamycin
Low
Report
Moleculin Announces Notice of Allowance for Japanese Patent Covering Annamycin
2/13
08:32 am
mbrx
Moleculin Launches CEO Corner Platform to Share Strategic Insights
Medium
Report
Moleculin Launches CEO Corner Platform to Share Strategic Insights
2/5
09:15 am
mbrx
Moleculin to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial
Medium
Report
Moleculin to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial
1/13
09:02 am
mbrx
Moleculin Reports Independent Assessment Confirms No Cardiotoxicity of Annamycin in 90 Subjects [Yahoo! Finance]
Medium
Report
Moleculin Reports Independent Assessment Confirms No Cardiotoxicity of Annamycin in 90 Subjects [Yahoo! Finance]
1/13
08:55 am
mbrx
Moleculin Reports Independent Assessment Confirms No Cardiotoxicity of Annamycin in 90 Subjects
Medium
Report
Moleculin Reports Independent Assessment Confirms No Cardiotoxicity of Annamycin in 90 Subjects
1/12
08:55 am
mbrx
Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding on Track, Global Trial Expansion, and Multiple Externally/IIT Funded Clinical Programs [Yahoo! Finance]
Low
Report
Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding on Track, Global Trial Expansion, and Multiple Externally/IIT Funded Clinical Programs [Yahoo! Finance]
1/12
08:36 am
mbrx
Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding on Track, Global Trial Expansion, and Multiple Externally/IIT Funded Clinical Programs
Low
Report
Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding on Track, Global Trial Expansion, and Multiple Externally/IIT Funded Clinical Programs